Fabry Disesase clinical trials at UCLA

1 research study open to eligible people

HM15421/GC1134A in Patients With Fabry Disease
open to eligible people ages 18 years and up
This Phase 1/2 first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15421 in patients with FD.
Los Angeles 5368361, California 5332921 and other locations

Last updated: September 17, 2025